Avexitide
Phase 3Active 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Post Bariatric Hypoglycemia
Conditions
Post Bariatric Hypoglycemia
Trial Timeline
Apr 29, 2025 → Oct 1, 2026
NCT ID
NCT06747468About Avexitide
Avexitide is a phase 3 stage product being developed by Amylyx Pharmaceuticals for Post Bariatric Hypoglycemia. The current trial status is active. This product is registered under clinical trial identifier NCT06747468. Target conditions include Post Bariatric Hypoglycemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06747468 | Phase 3 | Active |
Competing Products
20 competing products in Post Bariatric Hypoglycemia